Welcome to the 114th edition of Deep Tech Catalyst, the educational channel from The Scenarionist where science meets venture!
This week, we explore one of the most persistent misunderstandings in MedTech company building: what happens when founders apply conventional startup logic to a sector where validation, regulation, commercialization, and financing are deeply overlapped from the very beginning.
I sat down with Jon Bergsteinsson, Founder & Managing Partner at LIFA Ventures, to unpack how an investor evaluates early-stage companies, why many founders ask the wrong questions at the start, and how the most credible companies align product development, go-to-market strategy, regulatory planning, and fundraising far earlier than most teams expect.
Key takeaways from the episode:
🏗️ Validation, Prototyping, Regulation, and Go-to-Market Must Evolve Together
In MedTech, these are not separate stages that can be handled one by one. The strongest companies build them as an interconnected system from the outset, rather than treating commercialization and scalability as downstream concerns.
📍 Go-to-Market Strategy Determines Regulatory Strategy
Regulatory planning should not be chosen in isolation or based only on geography. It should follow from a clear understanding of who the product is for, who will use it, who will pay for it, and how the company intends to enter the market.
🧪 Clinical Development Is Also a Capital Planning Exercise
Clinical studies are not only scientific milestones. They are budgeting and financing milestones as well. Timelines, sample sizes, and study design all shape capital needs, and founders often underestimate how early those assumptions need to be made.
💰 Fundraising in Medtech Should Be Framed Around De-Risking, Not Venture Labels
Rounds such as pre-seed, seed, or Series A often fail to describe what is actually happening in a medtech company. A clearer approach is to define each raise by the specific technical, clinical, regulatory, or commercial risks it is meant to remove.
📈 Scalability Begins with Early Commercial Signals
Revenue is not the only meaningful sign of traction. Buyer interest, pricing feedback, reimbursement logic, and early distributor conversations can all provide strong evidence that the company is building toward a real market rather than just a promising technology.
The race for a faster way to get critical mineral supply | Rumors
Four startups, four technical paths, one shared bet: the fastest way to add critical mineral supply may come from existing material flows and installed assets, not just new mines.
